UK biotech Exscientia has taken a step towards its goal of having four drug candidates in clinical trials next year, after inheriting two precision oncology candidates tha
AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient gr
If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven
Exscientia's artificial intelligence-based drug discovery engine is still largely unproven, but that hasn't stopped the company raking in funding from investors keen to back its platform.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho